EXPRESS MAIL NO. EV 346 792 763 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of: Haim AVIV et al.

Confirmation No. 6729

pplication No.: 10/644,687

Group Art Unit: 1626

Filing Date:

August 19, 2003

ť

Examiner: Taofiq A. Solola

For: HIGH ENANTIOMERIC PURITY

Attorney Docket No.:

DEXANABINOL FOR PHARMACEUTICAL

87754-7500

COMPOSITIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. 1.56, enclosed are copies of eleven (11) further references for the Examiner's review and consideration. These references are listed on the enclosed Form PTO-1449. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the PTO Form 1449.

The fee which is believed to be due for this submission is \$180. Please charge the required fee to Winston & Strawn LLP Deposit Account No. 50-1814.

Respectfully submitted

Allan A. Fanucci

WINSTON & STRAWN Customer Number 28765

(212) 294-3311

03/16/2005 EABUBAK1 00000001 501814 10644687

01 FC:1806

180.00 DA

TPE.	40										,		
MAR O 9 TO	S J	·		,							Page	e 1 of 1	
							ATTY. DOCKET NO.:			APPLIC	APPLICATION NO.:		
& TRADE	MA			87754-7500			10/	10/644/687					
TPI	E JAST	OF REFERENCES CITE		APPLICANT:									
∖ lo,	(E)	(Use several sheets if n	ecessa	ry)			Haim AVIV et	al.					
, ,	MAR D 9 2005 SE						FILING DATE:			ŀ	GROUP:		
MAR	<u>\s</u>						August 19, 2003	3		161	4		
EVAMINE .	RADEMARE			U.S. F	PATEN	T DOCUM	IENTS	·	Т				
*EXAMINE INITIAL	, K	DOCUMENT NUMBER	c	DATE			NAME	·	CLASS	SUBCI		FILING DATE IF APPROPRIAT E	
	AA												
	AB												
				FOREI	GN PAT	TENT DOCU	JMENTS		1	<u> </u>			
	cont												
		DOCUMENT NUMBER		DATE			COUNTRY		ASS	SUBCLA SS	TRANSLA	ATION	
						333.711				. <u> </u>	YES	NO	
	AC												
	AD							3					
		OTHER REFI	EREN	CES (Inc	cluding	Author, Tit	le, Date, Pertinent Pag	ges, Etc.)					
	AE	Machaulam D. and Hanux I. "A Historical Overview Of Chemical Passarch On											
	AF	Mechoulam R. et al., "Synthesis Of The Individual, Pharmacologically Distinct, Enantiomers Of A Tetrahydrocannabinol Derivative", Tetrahedron Asymmetry, Vol. 1, No. 5, pp. 315-318, (1990).											
	AG	Ottani A. et al., "HU-210: A Potent Tool For Investigations Of The Cannabinoid System", CNS Drug Reviews, Vol. 7, No. 2, pp. 131-145, (2001).											
	AH	Levin S. et al. "Resolution Of Chiral Cannabinoids On Amylose Tris(3, 5-dimethylphenylcarbamate) Chiral Stationary Phase: Effects Of Structural Features And Mobile Phase Additives", Journal of Chromatography A., Vol. 654, pp.53-64, (1993).											
	AI	Pop E. et al, "Derivatives Of Dexanabinol I. Water-Soluble Salts Of Glycinate Esters", Pharmaceutical .Research, Vol. 13, pp. 62-69, (1996).											
	AJ	Pop E. et al., "Derivatives Of Dexanabinol II. Salts Of Amino Acid Esters Containing Tertiary And Quaternary Heterocyclic Nitrogen With Increased Water-Solubility", Pharmaceutical Research, Vol. 13, pp469-475, (1996).											
	AK	Pop E. et al. "In Vitro And In Vivo Study Of Water-Soluble Prodrugs Of Dexanabinol", Pharmaceutical Research Sciences, Vol. 88, pp. 1156-1160, (1999)											
	AL	Pop E. et al, "Water-Soluble Combinations Of Dexanabinol: Prodrugs And Analogs", Pharmazie, Vol. 55, pp 167-171, (2000)											
	AM Thomas B.F. et al., "Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency ¹ ", Journal Pharmacology and Experimental Therapeutics, Vol 255, pp. 624-630, (1990).									630,			

	OTHER REFERENCES (Including Aut	thor, Title, Date, Pertinent Pages, Etc.)						
AN	Brewster M. E. et al, "Clinical Pharmacokinetics Of Escalating i.v. Doses Of Dexanabinol (HU-211), A Neuroprotectant Agent, In Normal Volunteers", International Journal Of Clinical Pharmacology and Therapeutics, Vol. 35, pp.: 361-365, (1997)							
AO	Knoller N. et al, "Dexanabinol (HU-211) In The Treatment Of Severe Closed Head Injury: A Randomized, Placebo-Controlled, Phase II Clinical Trial" Crit. Care Med., Vol 30, pp. 548-554, (2002)							
AP								
AQ								
AR								
AS								
•	EXAMINER	DATE CONSIDERED						
*EXAMINER: I		is in conformance with MPEP 609; Draw line through citation if not of this form with next communication to applicant						